Author

R. Khatri

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Cancer Biology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:host-pathogen & immune response· 3 Organism:human· 3 Research Focus:cell type annotation· 2 Assay:proteomics· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:development & morphogenesis· 1 Research Focus:differential expression· 1

Frequent Co-Authors

S. Samal· 2 shared A. Awasthi· 1 shared A. Binayke· 1 shared A. C. Faber· 1 shared A. K. Yu· 1 shared B. Hu· 1 shared C. Costa· 1 shared C. H. Benes· 1 shared

Activity by Year

2018-2022 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

S. Samal

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Genomic screening reveals UBA1 as a potent and druggable target in c-MYC-high TNBC models

S. Jacob, T. H. Turner, J. Cai, K. V. Floros, A. K. Yu, C. M. Coon, R. Khatri, M. A. Alzubi, C. T. Jakubik, Y. M. Bouck, M. Puchalapalli, M. Shende, M. G. Dozmorov, S. Boikos, B. Hu, , A. C. Faber

The paper identifies UBA1 as a druggable target in c-MYC-high TNBC models, showing TAK-243 induces ER-stress and apoptosis in vitro and in vivo.

bioRxiv · May 17, 2022Cancer Biology

SARS-CoV-2 and its variants, but not Omicron, induces thymic atrophy and impaired T cell development

Z. A. Rizvi, S. Sadhu, J. Dandotiya, A. Binayke, P. Sharma, V. Singh, V. Das, R. Khatri, R. Kumar, S. Samal, M. Kalia, A. Awasthi

This study shows SARS-CoV-2 and its variants cause thymic atrophy and impair T cell development, with Omicron having a lesser effect than Delta.

bioRxiv · Apr 7, 2022 · PreprintImmunology

Immunopharmacological evaluation of adjuvant efficacy of Monophosphoryl lipid-A and CpG ODN with SARS-CoV-2 RBD antigen

S. Sambyal, V. Sravanthi, R. Khatri, G. Siddiqui, S. Ahmed, S. Samal, H. M. Sampath Kumar

The paper evaluates the immunopharmacological efficacy of MPL-A and CpG ODN adjuvants with SARS-CoV-2 RBD antigen, showing they elicit potent antibody responses and enhance T and B cell populations.

bioRxiv · Apr 4, 2022 · PreprintImmunology

Increased association between Epstein-Barr virus EBNA2 from type 2 strains and the transcriptional repressor BS69 restricts B cell growth

R. Ponnusamy, R. Khatri, P. B. Correia, E. Mancini, P. J. Farrell, M. J. West

This study identifies a third BS69 binding motif in type 2 EBNA2 that restricts B cell growth by enhancing EBNA2-BS69 interaction, explaining reduced transformation efficiency of type 2 EBV.

bioRxiv · Nov 7, 2018Microbiology